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Abstract
Background: The measurement of health, the effects of disease, and the impact of health care
include not only an indication of changes in disease frequency and severity but also an estimate of
patients' perception of health status before and after treatment. One of the more important
developments in health care in the past decade may be the recognition that the patient's
perspective is as legitimate and valid as the clinician's in monitoring health care outcomes. This has
lead to the development of instruments to quantify the patients' perception of their health status
before and after treatment.
Methods: We review evidence supporting the measurement properties of the MacNew Heart
Disease Health-related Quality of Life [MacNew] Questionnaire which was designed to evaluate
how daily activities and physical, emotional, and social functioning are affected by coronary heart
disease and its treatment.
Results: Reliability was demonstrated by using internal consistency and the intraclass correlation
coefficients for the three domains in the Dutch, English, Farsi, German, and Spanish versions of the
MacNew. With internal consistency and intraclass correlation coefficients =>0.73, reliability is high.
Validity of the MacNew was examined with factor analysis and three core underlying factors,
physical, emotional, and social, were identified, explaining 63.0 – 66.5% of the observed variance
and replicated in the translations with psychometric data. Construct validity of the MacNew was
further demonstrated by extensive substantiation of the logical relationships, defined a priori,
between items and other comparison tools. The MacNew is responsive and sensitive to changes in
HRQL following various interventions for patients with heart disease with 11 of 13 effect size
statistics >0.80. Taking an average of 10 minutes or less to complete, the respondent-burden for
the MacNew is low and its acceptability is demonstrated by response rates of over 90%. Normative
data are available for patients with myocardial infarction, angina, and heart failure in the English
version.
Conclusion: The MacNew may be a valuable tool for assessing and evaluating health related
quality of life in patients with heart disease.
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One of the more important developments in health care
in the past decade may be the recognition that the
patient's perspective is as legitimate and valid as the clini-
cian's in monitoring health care outcomes [1,2]. The
added value in better understanding the impact of disease
from the patient's perspective has led to the development
of instruments to quantify the patients' perception of their
health status before and after treatment. Traditional out-
comes of treatment for coronary heart disease such as
mortality and objective physiological or exercise tests give
little information about the impact of either the condition
or treatment from the patient's perspective.
Health-related quality of life [HRQL] has been defined by
various authors; examples include HRQL as a measure of
the patient's perspective representing the "functional
effect of an illness and its consequent therapy upon a
patient, as perceived by the patient" [3] and that proposed
by Patrick and colleagues [4] as "the value assigned to
duration of life as modified by the impairments, func-
tional states, perceptions, and social opportunities that
are influenced by disease, injury, treatment, or policy".
HRQL is now considered an important outcome measure
in investigations of therapeutic interventions for patients
with chronic conditions such as cancer and heart disease,
in epidemiological studies and in patient care, represent-
ing a paradigm shift in the assessment of efficacy and
effectiveness [5]. This paradigm shift is partly a result of
the introduction of a "biopsychosocial" perspective in
medicine [6]. Coronary heart disease is the major cause of
disability in many developed regions and by 2020 is fore-
cast to be the major cause of disease burden world-wide
[7]. Patients who survive an acute coronary event may live
for an extended period of time but often may be disabled,
helping to drive the increased attention in HRQL out-
comes in studies of coronary heart disease [5]. As an out-
come measure HRQL more pragmatically represents what
patients say about how they feel and function in their
daily lives as result of a disease or treatment and it gener-
ally includes, at a minimum, items about physical func-
tion and symptoms, psychological state, and social
interaction [3,4,8].
When choosing an HRQL instrument, the researcher or
clinician needs to ask "has an instrument been developed
and tested for the purpose for which it is to be used and
does it meet my needs?" Asking this question can give
direction to reading the literature and will help the
researcher or clinician select the instrument best suited for
the specific purpose. There are a number of heart disease
specific HRQL instruments. Most are designed for a partic-
ular heart disease diagnosis, for example, the Seattle
Angina Questionnaire [9], the Minnesota Living with
Heart Failure questionnaire [10], the Kansas City Cardio-
myopathy Questionnaire [11], and the recently published
Myocardial Infarction Dimensional Assessment Scale
[12].
For HRQL instruments to be useful, not only must they
demonstrate acceptable validity criteria, they must also
exhibit good discriminative, evaluative, and predictive
properties [13]. A discriminative instrument is designed to
distinguish between individuals or groups at a single
point in time, e.g., good and poor HRQL, and needs to
demonstrate reliability. An evaluative instrument is used
when one needs to measure change in HRQL over time,
e.g., as a result of an intervention, and needs to be respon-
sive. A predictive instrument classifies individuals into a set
of predefined measurement categories, e.g., alive or dead.
Another key property of both discriminative and evalua-
tive instruments is interpretability, i.e., can the differences
between subjects at a single point in time be identified by
discriminative instrument as trivial, small, moderate, or
large and can the changes within subjects over time be
identified by evaluative instruments as trivial, small, mod-
erate, or large?
In this article, we review evidence concerning the meas-
urement properties of the MacNew Heart Disease Health-
related Quality of Life [MacNew] Questionnaire [14,15].
This instrument is a modification of the Quality of Life
after Myocardial Infarction [QLMI] Questionnaire which
was originally developed nearly 20 years ago for patients
who had survived an acute myocardial infraction [MI] and
who were referred for subsequent cardiac rehabilitation
[16].
The Original Quality of Life after Myocardial 
Infarction [QLMI] Questionnaire
The original interviewer-administered QLMI was devel-
oped for use in a trial of cardiac rehabilitation in moder-
ately anxious and/or depressed patients with a
documented MI [16]. It was designed to assess a patient's
feelings about a range of issues and concerns identified by
individuals who have suffered an acute MI and includes
items addressing physical [and somatic], psychological,
and social domains. The QLMI was designed to evaluate
how daily activities, as well as physical, emotional, and
social functioning are affected by the disease and its treat-
ment for the disease.
The original QLMI items were generated through inter-
views with physicians, nurses, allied health professionals,
patients with MI, and by reviewing the literature [17]. The
item reduction instrument consisted of 97 items. It was
administered to a group of 63 patients who were recruited
from a cardiac rehabilitation program, 3 community hos-
pitals, and volunteer patients from the community. There
were 57 males and 6 females (mean age 58.0 years) whoPage 2 of 8
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25% 3 to 6 months, and 6% >12 months previously.
Patients were asked to identify items of concern to them,
and to rate those items from 1 [not very important] to 5
[very important]. A clinical impact score was generated by
multiplying the number of patients rating an item as of
concern by the mean score of that item [18]. The items
with the highest scores were selected to form the inter-
viewer-administered QLMI Questionnaire. The items of
the original QLMI instrument were conceptually assigned
to five domains [symptoms, restrictions, confidence, self-
esteem and emotion] [17] without including factor ana-
lytical strategies to confirm the theoretically assumed five-
factor structure. The internal consistency of the original
QLMI domains ranges from 0.75 to 0.87 [17]. A priori
hypotheses to determine the discriminative and evalua-
tive validity of the items in the QLMI were tested against
several well established clinical measures [e.g. State-Trait
Anxiety Inventory, Beck Depression Inventory, Profile of
Mood Scale, Time Trade-off, Quality of Well-Being, Katz
social functioning instrument, and a symptom limited
exercise test]. Twenty-eight out of 34 hypotheses were
accepted confirming the discriminative construct validity
of the items [17]. Although the evaluative validity of the
QLMI was not as robust as its discriminative validity [17],
the responsiveness of the instrument has since been dem-
onstrated in a number of studies [see the section on
responsiveness below].
The MacNew Heart Disease Health-related 
Quality of Life instrument
The MacNew Heart Disease HRQL questionnaire [Mac-
New] is a self-administered modification of the original
QLMI instrument [14,15]. The MacNew consists of 27
items which fall into three domains [a 13-item physical
limitations domain scale, a 14-item emotional function
domain scale, and a 13-item social function domain
scale]. There are 5 items that inquire about symptoms:
angina/chest pain, shortness of breath, fatigue, dizziness,
and aching legs. The time frame for the MacNew is the pre-
vious two weeks.
Scoring of the MacNew is straight-forward. The maximum
possible score in any domain is 7 [high HRQL] and the
minimum is 1 [poor HRQL]. Missing responses do not
contribute to the score and item 27, 'sexual intercourse',
may be excluded without altering the domain score as
each domain score is calculated as the average of the
responses in that domain. For example, if only 10 of the
14 Emotional items are answered, the Emotional Score is
the average of 10 responses. If more than 50% of the items
for a domain are missing, the score for that domain is not
calculated, that is, it is considered to be missing. The
instrument also has a global HRQL score which can be
calculated as the average over all scored items unless one
of the domains is completely missing [14,15]. In addition
to the 11 studies reported below which provide psycho-
metric data [14,15,17,19-26], the MacNew has been suc-
cessfully administered, to our knowledge, in at least 12
clinical and/or experimental studies [16,27-37] to more
than 5,200 patients with heart disease
Psychometric properties
A disease specific HRQL instrument is one step towards
individualizing the measurement of a patient's quality of
life [38]. As either a discriminative or evaluative instru-
ment it should meet the basic criteria for acceptable psy-
chometric properties which include validity, reliability,
responsiveness, and interpretability [39].
Reliability
Test reliability is the degree to which the test is free from
random error [39]. The assessment of reliability includes
two main forms: internal consistency and reproducibility.
Internal consistency is typically assessed by Cronbach's
alpha, while reproducibility can be assessed by test-retest
and intraclass correlation coefficients [39]. Table 1
presents the available data on the internal consistency and
reproducibility of the QLMI and the Dutch, English, Farsi,
German, and Spanish versions of the MacNew.
Internal consistency for the three domains in the English
version of the MacNew ranges from 0.93 to 0.95 [15] and
ranges from 0.75 to 0.97 in the Dutch [De Gucht, manu-
script under review], Farsi [24], German [23,26], and
Spanish [21] versions of the MacNew [Table 1]. As dis-
criminative instruments measure differences between
subjects, the intraclass correlation is usually considered to
be the better indicator for reproducibility as it accounts for
a possible systematic difference of the replicated measure-
ments [39]. The intraclass correlation coefficients range
from .73 – .95 in the international versions [21,23,24,26]
[Table 1]. Test-retest correlations of the MacNew indicate
acceptable reproducibility on separate occasions in
patients with myocardial infarction and angina with
ranges from rtt = .61 – .87 in the English [17], Spanish [21]
and German versions [23,26]. In the Farsi version, the
test-retest correlations, although significant, are lower but
this most likely because patients did not necessarily meet
criteria for clinical stability [24] [Table 1].
Overall the MacNew is reliable and meets the reproduci-
bility standard of 0.70 for group comparison which usu-
ally is the goal in clinical trials [39].
Validity
A test is valid when it measures what it purports to meas-
ure. Three forms of validity are commonly recognized:
face and content validity, construct-related validity and
criterion-related validity. The last, however, can bePage 3 of 8
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criterion measure [gold standard] [39]. In addition, pre-
dictive validity is an additional useful form of validity for
HRQL instruments.
Face and content validity
Face and content validity of the MacNew were established
during the process of developing the MacNew [17].
Construct-related validity
Construct-related validity of the MacNew as a discrimina-
tive instrument was carried out initially on the English
version MacNew, and subsequently on various language
translations. Construct validity was assessed by examining
the logical relations that should exist with other measures
and by using the "known-group" comparison strategy
[40]. Development of the MacNew incorporated psycho-
metric testing using principal component factor analytical
approaches identifying three core underlying factors:
physical, emotional and social [14,15]. These three
domains explain between 63.0% and 66.5% of the vari-
ance [14,15]. Extensive substantiation of the logical rela-
tionships between the items, defined a priori, further
demonstrated the discriminative construct validity of the
MacNew [14,15]. For example, Lim et al [14] used gender,
previous MI, coronary artery bypass surgery, readmission
to hospital, positive attitude to exercise and dietary habits,
and perceived threat of further heart problems while Val-
enti and colleagues [15] used age, gender, previous MI,
coronary artery bypass surgery, and readmission to hospi-
tal as the discriminating factors.
Principal component factor analytical approaches have
substantially confirmed the three factor (physical, emo-
tional and social) structure of the original MacNew model
[14,15] in each of the independently generated Dutch
[items #24, 25, 26 were omitted from this version] [De
Gucht, manuscript under review], Farsi [24], and Spanish
[21] translations of the MacNew. Structural equation
modeling used with the German version for MI patients
also substantially confirmed the three factor structure
[26]. In the original factor analyses [14,15], the decision
was made to include any item with a factor weight of
=>0.40 in that domain which meant that any one item
could fall into more than one domain. Of the 26 items,
five items were allocated to the emotional and social
domains, five to the physical and social domains, one to
the emotional and physical domains, one to all three
Table 1: Internal consistency, reproducibility and responsiveness statistics for the English [n = 352], Dutch [n = 339], Farsi [n = 51], 
German [n = 357], and Spanish [n = 143] versions of the MacNew Heart Disease Health-related Quality of Life Questionnaire
English Dutch Farsi German Spanish
Cronbach's α
Physical .93 .86–.91 .92 .86 – .90 .88
Emotional .95 .91–.92 .92 .97 .85
Social .95 .78–.84 .94 .93 – .95 .83
Global NA¶ .92–.95 .95 .93 – .97 NA¶
Test-Retest rtt
Physical .83 & .75* NA¶ .38 .68 – .87 .81
Emotional .86** NA¶ .42 .63 – .72 .78
Social .87 & .85‡ NA¶ .31 .61 – .83 .71
Global .86‡‡ NA.¶ .50 .65 – .81 NA¶
Intraclass 
Correlation
Physical NA¶ NA¶ .92 .73 – .93 .87
Emotional NA¶ NA¶ .92 .77 – .84 .83
Social NA¶ NA¶ .93 .75 – .91 .83
Global NA¶ NA¶ .95 .76 – .81 NA¶
Effect size
Physical .27 & 1.34* 1.38 NA¶ .86 NA¶
Emotional .57** .81 NA¶ .94 NA¶
Social 1.43 & .85‡ 1.11 NA¶ .99 NA¶
Global 1.22‡‡ 1.18 NA¶ 1.12 NA¶
¶ Not available * Symptoms and restrictions scales for QLMI at 12 months [n = 201] [17] ** Emotions scale in QLMI at 12 months [n = 201] [17]‡ 
Confidence and self-esteem scales in QLMI at 12 months [n = 201] [17]‡‡ Global score in QLMI at 12 months [n = 201] [17]Page 4 of 8
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ity of this approach may be questioned and is presently
being examined.
There apparently is relatively little impact of the different
languages on the international "harmonization" of the
original three factor structure. The highest factor weight
for each item in each language is identified in Table 2 with
the checks identifying the domain to which the item was
allocated the original English factor analysis [15]. Of the
26 items, 25 [96%] matched the domain with the highest
weighting in the original English analysis in at least two of
the four languages and 15 [58%] items matched in at least
three of the four languages; one item, #6, originally allo-
cated to the emotional domain, matched in only one of
the other four languages."
These independent international studies also used other
approaches to demonstrate discriminative construct valid-
ity and found significant correlations with the relevant
concepts of each of the different instruments used. In the
Dutch study the authors used the Heart Patient's Psycho-
logical Questionnaire and the Symptom Checklist to
demonstrate construct validity [De Gucht, manuscript
under review]. The SF-36 was used to confirm convergent
validity in Austrian samples of angina patients and MI-
patients [23,26]. The "known-group" approach, using
established clinical indicators, was carried out in MI and
angina patients as an additional way to establish validity.
Patients were grouped according to clinical measures of
disease severity, for example by the Canadian Cardiovas-
cular Society and the New York Heart Association classifi-
cation scales [23,25] or by either previous myocardial
infarction, rehospitalization, or surgery [14,15]. MacNew
domain scores of the groups differed in the directions
expected, confirming the discriminative properties of the
MacNew.
Predictive validity
The predictive validity of the MacNew has been examined
by Lim and colleagues [19]. They tested the hypothesis
that low HRQL after discharge from hospital with
ischemic heart disease is associated with higher rates of
adverse events [death or re-hospitalization] in 375
patients. The median [and interquartile ranges] Global
domain scores were 4.1 [3.6–4.6] for the low HRQL
group, 5.6 [5.3–5.9] for the moderate HRQL group, and
6.5 [6.2–6.7] for the high HRQL group and each of these
Table 2: Items [with the highest factor weightings =>0.40] as allocated to each domain in the original English version of the MacNew 
[ ] and the Dutch [D], Farsi [F], German [G], and Spanish [S] versions of the MacNew
Item Emotional Physical Social
1. Frustrated D, G, S F
2. Worthless D, G F, S
3. Confident D, G, S F
4. Down in the dumps D, G, S F
5. Relaxed D, F, G, S
6. Worn Out S D, G F
7. Happy with Personal Life D, F, G, S
8. Restless D, F, G, S
9. Short of Breath D, F, G, S
10. Tearful D, G F, S
11. More Dependent D, F, S
12. Social Activities D, F, G, S
13. Others/less Confidence in you G D, F, S
14. Chest Pain D, G, S F
15. Lack Self-Confidence D, G F, S
16. Aching Legs D, F, G, S
17. Sports/Exercise Limited D, S F, G
18. Frightened D, G F S
19. Dizzy/Lightheaded S D, G
20. Restricted or Limited D, S F, G
21. Unsure about Exercise D, S F, G
22. Overprotective Family D, G, S
23. Burden on Others D, F, G, S
24. Excluded S F, G
25. Unable to Socialize F, G, S
26. Physically Restricted S F, G
9
9
9
9
9
9
9
9
9
9
9
9
9
9
9
9
9
9
9
9
9
9
9
9
9
9
9Page 5 of 8
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the MacNew [see the interpretability section below]. An
odds ratio of 2.66 [95% confidence limits = 1.2 to 5.8] for
an adverse event in the next 24 months was observed in
patients in the lowest tertile for global MacNew HRQL at
discharge compared to those in the highest tertile with an
absolute adverse event rate of 28% in the low HRQL and
9% in the high HRQL group [19].
Overall these findings support the face and content, con-
struct, and predictive validity of the MacNew for evaluat-
ing HRQL in patients with heart disease and can be
recommended for international use.
Responsiveness
A test is responsive when it is sensitive to change. Respon-
siveness is an important psychometric property of an
HRQL instrument when the purpose is to evaluate treat-
ment effects over time, especially if they are small. It is
usually assessed with an effect size statistic [39]. The eval-
uative [longitudinal] validity, i.e., responsiveness, of the
MacNew has been tested with three different effect size
statistics, the effect size statistic [ES], the standardized
response mean [SRM], and the responsiveness statistic
[RS]. The denominator in each case is the difference
between groups with the standard deviation at baseline as
the numerator for the ES, the standard deviation of
change for the SRM, and the standard deviation in stable
patients for the RS.
As shown in Table 1, the SRM effect sizes over the longer
12-month follow-up period were moderate to strong
[SRM ranging from 0.57 to 1.43] for five of the six scales
[17]. The German version of the MacNew was adminis-
tered to angina patients at the time of angiography and
again at the 12-month follow-up following continued
medical or invasive treatment methods [23]. In this study,
the responsiveness of the German MacNew over the 12-
months is moderate using the ES and the SRM [0.30 to
0.47] but strong with the RS [0.86 to 1.12] [Table 1]. By
treatment, the ES was <0.27 with continued medical treat-
ment, ranged from 0.39 to 0.51 with percutaneous coro-
nary intervention, and from 0.60 to 0.70 with coronary
bypass surgery confirming the expected impact of differ-
ent interventions [23]. Limited data on the MacNew sug-
gest that HRQL is significantly improved in patients with
heart failure although no attempt was made to calculate
an effect size [36].
There are some comparative data for the responsiveness of
the MacNew and other HRQL instruments. For example,
using the RS analysis, the effect size for the MacNew phys-
ical domain, which measures a patient's perception of the
physical function, is 0.86 compared to 0.59 for the Seattle
Angina Questionnaire physical limitations domain which
measures a patient's physical performance [23]. On the
other hand, if the Seattle Angina disease perception and
the MacNew Global scores can be compared, the Seattle
disease perception domain RS is 1.48 and higher than the
RS observed for the German Global MacNew score at 1.12
[23]. In the Dutch study, the MacNew was considerably
more responsive [ES, 0.81 to 1.38] than either the Symp-
tom Checklist [ES, 0.11 to 0.67] or the Heart Patient's Psy-
chological Questionnaire [ES, 0.06 to 0.28] [De Gucht,
manuscript under review]. Further, there is additional
experimental evidence for the responsiveness of the QLMI
and MacNew as an outcome measure in cardiac rehabili-
tation [28,32,37].
Overall, these observations suggest that, as an evaluative
instrument, the MacNew is responsive and sensitive to
changes in HRQL following various interventions for
patients with coronary heart disease.
Interpretability
Interpretability is concerned with the understanding of
the meaning of the instrument's quantitative scores, espe-
cially for change scores [39]. The minimal important dif-
ference is defined as "the smallest difference in score in
the domain of interest which patients perceive as benefi-
cial and which would mandate, in the absence of trouble-
some side effects and excessive cost, a change in the
patient's management" [41]. Dixon et al. [22] investigated
the minimal important difference for the MacNew
domain scores, hypothesizing that scores of successfully
revascularized patients would increase, that scores of read-
mitted patients would decrease, and that the scores of the
remainder would be relatively stable. They were able to
demonstrate that a change of at least 0.5 is a useful indi-
cator of the minimal important difference for all 3 scales
and the global score [22]. This observation has since been
substantiated in other work [25,36,42]. Dixon and col-
leagues [22] have provided the user of the English-version
MacNew with normative data which are available by diag-
nosis [myocardial infarction, angina, and heart failure]
and age [<65, 65–74, and 75–85 years].
Respondent and administrative burden
The MacNew has a low respondent-burden [14,15,23,26]
taking on average 10 minutes or less to complete, and its
acceptability is demonstrated by response rates of over
90%. With the availability of SPSS-Syntax to score the
MacNew, there is also little researcher-burden.
Availability and Cost of the MacNew
The MacNew is copyrighted by the developers for the pur-
pose of maintaining an unmodified version in order to
preserve the integrity of the instrument. As the MacNew is
considered to be in the public domain, there is no cost for
permission to use the MacNew or its translations. How-Page 6 of 8
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citations in their publications and provide the developers
of the MacNew with published data to further develop the
instrument.
The original English version of the MacNew and its trans-
lations into Chinese [Cantonese], Danish, Dutch, Farsi,
Finnish, French, German, Greek, Hebrew, Italian, Lithua-
nian, Norwegian, Polish, Portuguese, Romanian, Russian,
Spanish, Swedish and Turkish are available from the
developers of the MacNew. The basic descriptive informa-
tion on the MacNew is available on the QOLID website at
http://www.qolid.org/.
Conclusion
HRQL provides researchers and clinicians with valuable
additional information about the impact of either the
condition or treatment from the patient's perspective, par-
ticularly in chronic diseases such as coronary heart disease
which is a major cause of disability. We believe that the
MacNew Heart Disease Health-related Quality of Life
instrument meets the established criteria for the psycho-
metric properties of instrument reliability, validity, and
responsiveness for use in patients with myocardial infarc-
tion and in patients with angina. The English and the Ger-
man MacNew are presently being tested, with
considerable preliminary promise, in patients with heart
failure. Psychometric assessment of the German MacNew
in pacemaker patients is nearing completion. Further,
tests of the psychometric properties of eleven of the
MacNew translations are underway in patients with myo-
cardial infarction, with angina, and with heart failure in
an international study which is being coordinated
through the Working Group on Cardiac Rehabilitation
and Exercise Physiology of the European Society of
Cardiology.
Contact to obtain the MacNew
The MacNew package containing a brief description of the
instrument, citations, the scoring algorithm, and the Mac-
New questionnaire can be obtained from the following:
Neil Oldridge, PhD
Center for Urban Population Health
University of Wisconsin-Milwaukee
1020 N. 12th Street, OHC 4th Floor
Milwaukee, WI 53201-0342
Telephone: 414-219-4084
Fax: 414-219-6563
Email neilb@uwm.edu
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